摘要
目的评估利拉鲁肽联合瑞格列奈对2型糖尿病患者血糖和胰岛素抵抗的影响。方法选取2016年5月—2019年5月收治的2型糖尿病患者60例为研究对象,按是否联合应用瑞格列奈分为研究组和对照组,每组30例。对照组给予利拉鲁肽治疗,研究组给予利拉鲁肽联合瑞格列奈治疗。比较2组治疗前后的空腹血糖(FPG)、餐后2 h血糖(2 hPG)、糖化血红蛋白(HbA1c)、肿瘤坏死因子-α(TNF-α)、白介素-1β(IL-1β)、超敏C反应蛋白(hs-CRP)、胰岛素抵抗指数(HOMA-IR)以及β-细胞功能指数(HOMA-β)水平,并观察不良反应发生情况。结果治疗后,2组FPG、2 hPG、HbA1c、IL-1β、TNF-α、hs-CRP水平均明显低于治疗前,且研究组均明显低于对照组(P<0.05)。治疗后,研究组的HOMA-β以及HOMA-IR水平较治疗前明显改善,且HOMA-β水平明显高于对照组,HOMA-IR水平明显低于对照组(P<0.05)。2组不良反应总发生率比较差异无统计学意义(P>0.05)。结论利拉鲁肽联合瑞格列奈治疗2型糖尿病,可以有效控制患者血糖,降低胰岛素抵抗情况,改善机体炎性反应状态,具有较高的安全性。
Objective To evaluate the effects of Lilarutide combined with Repaglinide on blood glucose and insulin resistance in patients with type 2 diabetes mellitus(T2DM).Methods A total of 60 patients with T2DM who were treated from May 2016 to May 2019 were selected as the research subjects.They were divided into research group(n=30)and control group(n=30)according to application of combination therapy with Rigaglinide.The control group was treated with Liraglutide,while the research group was treated with Liraglutide combined with Regglinide.The fasting blood glucose(FPG),2 h postprandial blood glucose(2 hPG),glycosylated hemoglobin(HbA1c),tumor necrosis factor-α(TNF-α),interleukin-1β(IL-1β),high sensitive C-reactive protein(hs-CRP),insulin resistance index(HOMA-IR)andβ-cell function index(HOMA-β)were compared before and after treatment in the two groups,and the adverse reactions were observed.Results After treatment,the levels of FPG,2 hPG,HbA1c,IL-1β,TNF-αand hs-CRP in the two groups were significantly lower than those before treatment,and those in the research group were significantly lower than those in the control group(P<0.05).After treatment,the level of HOMA-βand HOMA-IR in the research group was significantly improved compared with that before treatment,and the level of HOMA-βwas significantly higher than that in the control group,while the level of HOMA-IR was significantly lower than that in the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Lilarutide combined with Repaglinide in the treatment of T2DM can effectively control the patient's blood glucose,reduce insulin resistance,and improve the inflammatory response of the body,with higher safety.
作者
华燕
蒋成霞
刘欣
HUA Yan;JIANG Cheng-xia;LIU Xin(Department of Endocrinology,the Second People's Hospital of Yibin,Yibin,Sichuan 644000,China)
出处
《解放军医药杂志》
CAS
2020年第3期79-82,共4页
Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
基金
四川省卫生和计划生育委员会科研基金资助项目(18PJ212)。